Abstract Yersinia is a genus of bacteria that includes several species known to cause diseases in humans and animals. We explore developments in anti-bacterial compounds to counteract Yersinia infections, focusing on both traditional antibiotic therapies and novel strategies targeting virulence factors, host-pathogen interactions, and vaccine development. This review evaluates current strategies for the treatment and management of Yersinia infections, outlining key challenges and emerging opportunities for improved clinical outcomes.
Gahlot et al. (Sat,) studied this question.